Medical Breakthroughs Reliant on Better Clinical Trials
MANASSAS, Va. , Nov. 7, 2023 /PRNewswire-PRWeb/ -- The dropout rate for clinical trials has long plagued researchers with evidence indicating that sometimes more than 30% of patient dropout during phase 3 clinical trials.(1) A substantial figure, this reality is detrimental not only to the studies themselves but also to the health and wellbeing of all those who may need but will not receive potentially life altering medical help for their conditions. Dr. Harsha Rajasimha, Founder and CEO of Jeeva Informatics, wants clinical trial sponsors and operators to understand what causes these high dropout rates and why it is so important to minimize them. Dr. Rajasimha feels greater remote accessibility for trial participants is key. "We want to make clinical trials universally accessible and more efficient."
- MANASSAS, Va. , Nov. 7, 2023 /PRNewswire-PRWeb/ -- The dropout rate for clinical trials has long plagued researchers with evidence indicating that sometimes more than 30% of patient dropout during phase 3 clinical trials.
- "We want to make clinical trials universally accessible and more efficient."
- Dr. Rajasimha says the one of the key goals of Sponsors should be to mitigate these risks of patient dropout in clinical trials.
- "By accelerating the standardized adoption of decentralized clinical trials, Sponsors can achieve efficiency and accessibility for all patients who may seek them.